Zyversa Therapeutics, Inc.2025财年第一财季实现净利润-2.26百万美元，同比增加20.14%

市场透视2025-05-19

5月19日，Zyversa Therapeutics, Inc.（ZVSA.US）公布财报，公告显示公司2025财年第一财季净利润为-2.26百万美元，同比增加20.14%；其中营业收入为0.00美元，每股基本收益为-0.73美元。从资产负债表来看，Zyversa Therapeutics, Inc.（ZVSA.US）总负债12.86百万美元，其中短期债务0.00美元，资产负债比为1.64，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536594380?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536594380","market":"us","top_or_hot":-1,"title":"Zyversa Therapeutics, Inc.2025财年第一财季实现净利润-2.26百万美元，同比增加20.14%","media":"市场透视","content":"<div>\n<p>5月19日，Zyversa Therapeutics, Inc.（ZVSA.US）公布财报，公告显示公司2025财年第一财季净利润为-2.26百万美元，同比增加20.14%；其中营业收入为0.00美元，每股基本收益为-0.73美元。从资产负债表来看，Zyversa Therapeutics, Inc.（ZVSA.US）总负债12.86百万美元，其中短期债务0.00美元，资产负债比为1.64，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000423a482f0e5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zyversa Therapeutics, Inc.2025财年第一财季实现净利润-2.26百万美元，同比增加20.14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZyversa Therapeutics, Inc.2025财年第一财季实现净利润-2.26百万美元，同比增加20.14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000423a482f0e5&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Zyversa Therapeutics, Inc.（ZVSA.US）公布财报，公告显示公司2025财年第一财季净利润为-2.26百万美元，同比增加20.14%；其中营业收入为0.00美元，每股基本收益为-0.73美元。从资产负债表来看，Zyversa Therapeutics, Inc.（ZVSA.US）总负债12.86百万美元，其中短期债务0.00美元，资产负债比为1.64，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000423a482f0e5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZVSA","symbol_name":"ZyVersa Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000423a482f0e5&s=b","article_id":"2536594380","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000423a482f0e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536594380","pubTimestamp":1747584072,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Zyversa Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-2.26百万美元，同比增加20.14%；其中营业收入为0.00美元，每股基本收益为-0.73美元。从资产负债表来看，Zyversa Therapeutics, Inc.总负债12.86百万美元，其中短期债务0.00美元，资产负债比为1.64，流动比率为0.18。机构评级：截至2025年5月19日，当前有1家机构对Zyversa Therapeutics, Inc.目标价做出预测，其中目标均价为20.00美元，其中最低目标价为20.00美元，最高目标价为20.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ZVSA":"ZyVersa Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Zyversa Therapeutics, Inc. achieved net profit of-US $2.26 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 20.14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVSA":0.9,"LENZ":1},"content_text":"5月19日，Zyversa Therapeutics, Inc.（ZVSA.US）公布财报，公告显示公司2025财年第一财季净利润为-2.26百万美元，同比增加20.14%；其中营业收入为0.00美元，每股基本收益为-0.73美元。从资产负债表来看，Zyversa Therapeutics, Inc.（ZVSA.US）总负债12.86百万美元，其中短期债务0.00美元，资产负债比为1.64，流动比率为0.18。机构评级：截至2025年5月19日，当前有1家机构对Zyversa Therapeutics, Inc.目标价做出预测，其中目标均价为20.00美元，其中最低目标价为20.00美元，最高目标价为20.00美元。公司简介：ZyVersa Therapeutics Inc 是一家临床阶段的生物制药公司，利用专有技术为医疗需求未得到满足的慢性肾脏或炎症性疾病患者开发药物。 该公司拥有两个专有的全球许可药物开发平台，即Cholesterol Efflux MediatorTM，VAR 200（2-羟丙基-β-环糊精）是一种处于临床开发阶段的用于治疗肾脏疾病的注射药物。 IC 100 是一种单克隆抗体炎性体 ASC 抑制剂，处于临床前开发阶段，用于治疗炎症。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536594380","isCrawlerRequest":true}